AP NEWS

Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 20, 2018

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec 20, 2018--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer will make a formal presentation at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta’s research and development programs. A question and answer session with investors will follow the presentation and will be webcast.

Webcast Information A live webcast of the presentation, as well as the question and answer session that follows the presentation, will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for approximately 60 days.

About Enanta Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Glecaprevir, a protease inhibitor discovered by Enanta, has been developed by AbbVie, and is now approved and sold in numerous countries as part of AbbVie’s newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Ongoing royalties from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and hepatitis B virus (HBV). Please visit www.enanta.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005046/en/

CONTACT: Investor Contact

Carol Miceli

617-607-0710

cmiceli@enanta.com

KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL

SOURCE: Enanta Pharmaceuticals, Inc.

Copyright Business Wire 2018.

PUB: 12/19/2018 03:23 PM/DISC: 12/20/2018 08:00 AM

http://www.businesswire.com/news/home/20181220005046/en

AP RADIO
Update hourly